The purpose of this study is to evaluate the safety and tolerability of 3 infusions of KD-247
over 2 weeks in HIV-1 seropositive individuals; to determine the pharmacokinetic parameters
of KD-247 when administered as above; and to assess the effect of KD-247 infusions on plasma
HIV-1 ribonucleic acid (RNA) load and on CD4+ T cell counts.